Literature DB >> 8621774

Primary preventive and secondary interventionary effects of acetyl-L-carnitine on diabetic neuropathy in the bio-breeding Worcester rat.

A A Sima1, H Ristic, A Merry, M Kamijo, S A Lattimer, M J Stevens, D A Greene.   

Abstract

The abnormalities underlying diabetic neuropathy appear to be multiple and involve metabolic neuronal and vasomediated defects. The accumulation of long-chain fatty acids and impaired beta-oxidation due to deficiencies in carnitine and/or its esterified derivatives, such as acetyl-L-carnitine, may have deleterious effects. In the present study, we examined, in the diabetic bio-breeding Worcester rat, the short- and long-term effects of acetyl-L-carnitine administration on peripheral nerve polyols, myoinositol, Na+/K+ -ATPase, vasoactive prostaglandins, nerve conduction velocity, and pathologic changes. Short-term prevention (4 mo) with acetyl-L-carnitine had no effects on nerve polyols, but corrected the Na+/K+ -ATPase defect and was associated with 63% prevention of the nerve conduction defect and complete prevention of structural changes. Long-term prevention (8 mo) and intervention (from 4 to 8 mo) with acetyl-L-carnitine treatment normalized nerve PGE(1) whereas 6-keto PGF(1-alpha) and PGE(2) were unaffected. In the prevention study, the conduction defect was 73% prevented and structural abnormalities attenuated. Intervention with acetyl-L-carnitine resulted in 76% recovery of the conduction defect and corrected neuropathologic changes characteristic of 4-mo diabetic rats. Acetyl-L-carnitine treatment promoted nerve fiber regeneration, which was increased two-fold compared to nontreated diabetic rats. These results demonstrate that acetyl-L-carnitine has a preventive effect on the acute Na+/- K+_ATPase defect and a preventive and corrective effect on PGE1 in chronically diabetic nerve associated with improvements of nerve conduction velocity and pathologic changes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8621774      PMCID: PMC507259          DOI: 10.1172/JCI118621

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

Review 1.  Glucose-induced metabolic imbalances in the pathogenesis of diabetic vascular disease.

Authors:  G Pugliese; R G Tilton; J R Williamson
Journal:  Diabetes Metab Rev       Date:  1991-03

Review 2.  Aldose reductase inhibitors: an approach to the treatment of diabetic nerve damage.

Authors:  D A Greene; A A Sima; M J Stevens; E L Feldman; P D Killen; D N Henry; T Thomas; J Dananberg; S A Lattimer
Journal:  Diabetes Metab Rev       Date:  1993-10

Review 3.  The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications.

Authors:  N E Cameron; M A Cotter
Journal:  Diabetes Metab Rev       Date:  1994-10

4.  Prevention and reversal of motor and sensory peripheral nerve conduction abnormalities in streptozotocin-diabetic rats by the prostacyclin analogue iloprost.

Authors:  M A Cotter; K C Dines; N E Cameron
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-05       Impact factor: 3.000

Review 5.  Hyperglycemic pseudohypoxia and diabetic complications.

Authors:  J R Williamson; K Chang; M Frangos; K S Hasan; Y Ido; T Kawamura; J R Nyengaard; M van den Enden; C Kilo; R G Tilton
Journal:  Diabetes       Date:  1993-06       Impact factor: 9.461

6.  Acetyl-L-carnitine corrects electroretinographic deficits in experimental diabetes.

Authors:  S Lowitt; J I Malone; A Salem; W M Kozak; Z Orfalian
Journal:  Diabetes       Date:  1993-08       Impact factor: 9.461

7.  Acetyl-L-carnitine enhances the response of PC12 cells to nerve growth factor.

Authors:  G Taglialatela; L Angelucci; M T Ramacci; K Werrbach-Perez; G R Jackson; J R Perez-Polo
Journal:  Brain Res Dev Brain Res       Date:  1991-04-24

8.  Neural dysfunction and metabolic imbalances in diabetic rats. Prevention by acetyl-L-carnitine.

Authors:  Y Ido; J McHowat; K C Chang; E Arrigoni-Martelli; Z Orfalian; C Kilo; P B Corr; J R Williamson
Journal:  Diabetes       Date:  1994-12       Impact factor: 9.461

9.  Production of 6-oxo-prostaglandin F1 alpha and prostaglandin E2 by isolated glomeruli from normal and diabetic rats.

Authors:  S P Rogers; R G Larkins
Journal:  Br Med J (Clin Res Ed)       Date:  1982-04-24

10.  Reaction of monosaccharides with proteins: possible evolutionary significance.

Authors:  H F Bunn; P J Higgins
Journal:  Science       Date:  1981-07-10       Impact factor: 47.728

View more
  16 in total

1.  Acetyl-L-carnitine ameliorates mitochondrial dysfunction following contusion spinal cord injury.

Authors:  Samir P Patel; Patrick G Sullivan; Travis S Lyttle; Alexander G Rabchevsky
Journal:  J Neurochem       Date:  2010-04-23       Impact factor: 5.372

Review 2.  Acetyl-L-carnitine in HIV-associated antiretroviral toxic neuropathy.

Authors:  Mike Youle
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

3.  Degeneration of the Golgi and neuronal loss in dorsal root ganglia in diabetic BioBreeding/Worcester rats.

Authors:  H Kamiya; W Zhang; A A F Sima
Journal:  Diabetologia       Date:  2006-09-20       Impact factor: 10.122

Review 4.  Pharmacological treatment of diabetic neuropathic pain.

Authors:  Howard S Smith; Charles E Argoff
Journal:  Drugs       Date:  2011-03-26       Impact factor: 9.546

5.  Advanced Diabetic Neuropathy: A Point of no Return?

Authors:  Petr Boucek
Journal:  Rev Diabet Stud       Date:  2006-11-10

Review 6.  Targeting neuroprotection as an alternative approach to preventing and treating neuropathic pain.

Authors:  Thierry Bordet; Rebecca M Pruss
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

7.  Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells.

Authors:  Hai Wei Jin; Sarah J L Flatters; Wen Hua Xiao; Howard L Mulhern; Gary J Bennett
Journal:  Exp Neurol       Date:  2007-11-17       Impact factor: 5.330

8.  L-acetylcarnitine: a proposed therapeutic agent for painful peripheral neuropathies.

Authors:  S Chiechio; A Copani; F Nicoletti; R W Gereau
Journal:  Curr Neuropharmacol       Date:  2006-07       Impact factor: 7.363

Review 9.  Acetyl-L-carnitine in neuropathic pain: experimental data.

Authors:  Santina Chiechio; Agata Copani; Robert W Gereau; Ferdinando Nicoletti
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 10.  Acetyl-L-carnitine in diabetic polyneuropathy: experimental and clinical data.

Authors:  Anders A F Sima
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.